Compare EPAM Systems Inc (EPAM) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Cassava Sciences Inc — how do they compare? EPAM Systems Inc trades at $99.55 (market cap $5.15B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: EPAM Systems Inc is far larger — about 107.9× Cassava Sciences Inc's market cap, and EPAM Systems Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EPAM | FLNA | |
|---|---|---|
Market Cap | $5.15B | $47.75M |
Sector | Technology | Health |
52-Week High | $221.40 | $4.64 |
52-Week Low | $76.04 | $0.87 |
Enterprise Value | $4.52B | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $99.00, up 1.67% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net margin of 7.15%. Recent news highlights strong Q2 2026 earnings but a lowered revenue outlook due to slower North American growth and a new OpenAI partnership.
Outlook is mixed: strong fundamentals and analyst consensus ($117.27 target) support upside, but technical weakness and growth headwinds pose risks. Investment opportunity lies in valuation discount and AI initiatives, countered by demand volatility and competitive pressures.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
